Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 979748, 7 pages
Research Article

Cytokine Patterns in Brain Tumour Progression

1Victor Babes National Institute of Pathology, 99-101 Splaiul Independentei, 050096 Bucharest, Romania
2National Institute for Chemical Pharmaceutical R&D, 112 Calea Vitan, 031299 Bucharest, Romania
3Stefan S Nicolau Institute of Virology, 285 Soseaua Mihai Bravu, 030304 Bucharest, Romania
4Neurology and Neurovascular Diseases National Institute, 10-12 Soseaua Berceni, 041914 Bucharest, Romania
5Elias Emergency University Hospital, 19 Bulevardul Marasti, 011462 Bucharest, Romania

Received 4 March 2013; Accepted 4 June 2013

Academic Editor: Gila Moalem-Taylor

Copyright © 2013 Radu Albulescu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Inflammation represents the immune system response to external or internal aggressors such as injury or infection in certain tissues. The body’s response to cancer has many parallels with inflammation and repair; the inflammatory cells and cytokines present in tumours are more likely to contribute to tumour growth, progression, and immunosuppression, rather than in building an effective antitumour defence. Using new proteomic technology, we have investigated serum profile of pro- (IL-1β, IL-6, IL-8, IL-12, GM-CSF, and TNF-α) and anti-inflammatory cytokines (IL-4, IL-10), along with angiogenic factors (VEGF, bFGF) in order to assess tumoural aggressiveness. Our results indicate significant dysregulation in serum levels of cytokines and angiogenic factors, with over threefold upregulation of IL-6, IL-1β, TNF-α, and IL-10 and up to twofold upregulation of VEGF, FGF-2, IL-8, IL-2, and GM-CSF. These molecules are involved in tumour progression and aggressiveness, and are also involved in a generation of disease associated pain.